The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000648325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/03/2026
Date registered
Help: Date registered
29/05/2026
Date last updated
Help: Date last updated
29/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
29/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment (EQUILIBRIUM ADCS) – Part C
Scientific title
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment (EQUILIBRIUM ADCS) – Part C
Additional trial identifiers [1] 316788 0
CRN04894-331
Additional trial identifiers [2] 316789 0
EUCTR 2025-522648-42-01
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
ACTH-Dependent Cushing’s syndrome (ADCS) 341113 0
Condition category
Condition code
Metabolic and Endocrine 337227 337227 0 0
Other endocrine disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention: Atumelnant (CRN04894)
A potent and selective orally administered nonpeptide small molecule melanocortin 2 receptor (MC2R) competitive antagonist under development for the treatment of ACTH-Dependent Cushing’s syndrome and congenital adrenal hyperplasia. Atumelnant is provided as a film coated tablet for oral use.

Participant IP compliance will be monitored through an electronic clinical outcome assessment (eCOA system) requiring real-time documentation of dosing and administration, with ongoing review to assess adherence.
Participants will bring the study drugs on their visits so the study doctor can monitor the intake.

Intervention Model:
Part C: Open-label extension, single arm.

Part C will enroll 3 groups of participants:
- Group 1: Participants who completed either Part A or B of the study.
- Group 2: When Part B enrollment closes, any participants in screening for Part B who are deemed eligible for the study will have the opportunity to enroll in Part C.
- Group 3: Enrollment for participants with severe ADCS or cyclic ADCS occurs once an effective dose of atumelnant is determined in Part A.

In Part C, all participants will be assigned to atumelnant. All participants in the open-label part of the study, irrespective of prior treatment assignment, will initiate treatment with 80mg of atumelnant (or an alternative dose recommended by the Data Monitoring Committee) for up to 2 years. Participants with severe ADCS may receive 120 mg of atumelnant.

The standard B&R strategy in the treatment of ADCS involves inhibiting cortisol synthesis until the point of hypoadrenalism and replacing it with physiological dose of glucocorticoid (GC) replacement therapy.
Intervention code [1] 333476 0
Treatment: Drugs
Description of the comparator or control
Part C: Open label without control arm
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344747 0
To evaluate the long-term effect of atumelnant on mean urinary free cortisol (mUFC).
Timepoint [1] 344747 0
Week 102 post intervention commencement.
Primary outcome [2] 344748 0
To evaluate the long-term safety of atumelnant in participants with ADCS.
Timepoint [2] 344748 0
For safety parameters, events will be checked as they occur, quarterly up to week 102 post intervention commencement or at discontinuation.
Primary outcome [3] 344749 0
To evaluate the long-term tolerability of atumelnant in participants with ADCS.
Timepoint [3] 344749 0
For tolerability parameters, events will be checked as they occur, quarterly up to week 102 post intervention commencement or at discontinuation.
Secondary outcome [1] 459073 0
Evaluating the effect of atumelnant on specific pharmacodynamic(s) (PD) biomarkers.
Timepoint [1] 459073 0
Week 102 post intervention commencement.
Secondary outcome [2] 459074 0
Evaluating the effect of atumelnant on specific pharmacodynamic(s) (PD) biomarkers.
Timepoint [2] 459074 0
Week 102 post intervention commencement.
Secondary outcome [3] 459075 0
Evaluating the effect of atumelnant on specific pharmacodynamic(s) (PD) biomarkers.
Timepoint [3] 459075 0
Week 102 post intervention commencement.
Secondary outcome [4] 459076 0
Evaluating the effect of atumelnant on Quality of Life (QoL).
Timepoint [4] 459076 0
Week 102 post intervention commencement.

Eligibility
Key inclusion criteria
Part C:
Group 1:
-Part A Arm 1: Complete the 12-week Treatment Period on study drug or standard of care medication, or enter the OLE during the Week 6 evaluation using Guidance to the Investigator for Part A Arm 1, or are rescued due to hypercortisolism and, in the Investigator’s opinion, would benefit from participation in the OLE.
-Part A Arms 2, 3, and 4: Complete the 12-week Treatment Period on study drug or standard of care medication and, in the Investigator’s opinion, would benefit from participation in the OLE.
-Part B: Complete the 12-week Treatment Period on study drug or standard of care
medication and, in the Investigator’s opinion, would benefit from participation in
the OLE.
Group 2: Participants must meet Part B inclusion criteria*.
Group 3: New participants entering must meet the same inclusion criteria as
Parts A and B with the exception that individuals with severe ADCS or cyclic ADCS are allowed*.

*Part A and B inclusion criteria:
- Male or female, between 18 up to and including 74 years of age at the time of signing the ICF. Participants from 16 years of age may be included at sites located in the US.
- Participants must have confirmed ADCS. (Part C Group 3 only: protocol-defined cyclic or severe ADCS.)
- Morning plasma ACTH greater than 10 pg/mL during screening confirmed by the central laboratory and available prior to randomization on Day 1.
- Participants with de novo Cushing’s disease (pituitary Cushing’s syndrome), ectopic ACTH syndrome (EAS), or ADCS of uncertain etiology who are not eligible for surgery (eg, poor surgical candidates, surgically unapproachable tumors, who refuse to have surgical treatment, or surgical treatment is not available) and could benefit from chronic treatment with study drug for at least 4 months.
Minimum age
18 Years
Maximum age
74 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Group 1: Individuals in Part A or B who do not meet Part C inclusion criteria.
Group 2: Individuals who meet any Part B exclusion criterion*.
Group 3: New participants who meet any of the exclusion criteria for Part A and Part B*.

*Part A and B exclusion criteria:
- Use of some medications could lead participants to enter the Washout Period.
- History of bilateral adrenalectomy.
- History of major surgery within 1 month prior to screening.
- Pituitary surgery within 3 months of Day 1.
- Participants who received pituitary irradiation within 2 years (stereotactic radio surgery) or 3 years (conventional radiation) before enrolment (Day 1).
- Participants who have previously taken atumelnant.
- Participants who will not benefit from chronic treatment with study drug or have a life expectancy of less than 6 months.
- Clinically significant concomitant disease considered by the Investigator likely to affect safe participation in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Recruitment hospital [1] 29266 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 29267 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [3] 29268 0
Westmead Hospital - Westmead
Recruitment hospital [4] 29269 0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Recruitment postcode(s) [1] 45576 0
5000 - Adelaide
Recruitment postcode(s) [2] 45577 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 45578 0
2145 - Westmead
Recruitment postcode(s) [4] 45579 0
2010 - Darlinghurst
Recruitment outside Australia
Country [1] 27925 0
Argentina
State/province [1] 27925 0
Country [2] 27928 0
Austria
State/province [2] 27928 0
Country [3] 27929 0
Brazil
State/province [3] 27929 0
Country [4] 27930 0
Canada
State/province [4] 27930 0
Country [5] 27931 0
France
State/province [5] 27931 0
Country [6] 27932 0
Germany
State/province [6] 27932 0
Country [7] 27933 0
Italy
State/province [7] 27933 0
Country [8] 27934 0
Netherlands
State/province [8] 27934 0
Country [9] 27935 0
Poland
State/province [9] 27935 0
Country [10] 27936 0
Spain
State/province [10] 27936 0
Country [11] 27937 0
Sweden
State/province [11] 27937 0
Country [12] 27938 0
United Kingdom
State/province [12] 27938 0
Country [13] 27940 0
Peru
State/province [13] 27940 0

Funding & Sponsors
Funding source category [1] 321384 0
Commercial sector/Industry
Name [1] 321384 0
Crinetics Pharmaceuticals, Inc.
Country [1] 321384 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Crinetics Pharmaceuticals, Inc.
Address
Country
United States of America
Secondary sponsor category [1] 324127 0
None
Name [1] 324127 0
Address [1] 324127 0
Country [1] 324127 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319925 0
Central Adelaide Local Health Network HREC
Ethics committee address [1] 319925 0
Ethics committee country [1] 319925 0
Australia
Date submitted for ethics approval [1] 319925 0
13/10/2025
Approval date [1] 319925 0
16/12/2025
Ethics approval number [1] 319925 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148838 0
Prof David Torpy
Address 148838 0
Royal Adelaide Hospital, North Terrace, Port Road, Adelaide, SA 5000
Country 148838 0
Australia
Phone 148838 0
+61 8 7074 2813
Fax 148838 0
Email 148838 0
Contact person for public queries
Name 148839 0
Mrs. Sarie Gilooly
Address 148839 0
Allucent (Au) Pty Ltd, Level 7, 1 Martin Place, Sydney NSW 2000, Australia
Country 148839 0
Australia
Phone 148839 0
+61 2 8358 1558
Fax 148839 0
Email 148839 0
Contact person for scientific queries
Name 148840 0
Mrs. Sarie Gilooly
Address 148840 0
Allucent (Au) Pty Ltd, Level 7, 1 Martin Place, Sydney NSW 2000, Australia
Country 148840 0
Australia
Phone 148840 0
+61 2 8358 1558
Fax 148840 0
Email 148840 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.